MEQSEL (Trametinib Dimethylsulfoxide)-0.5mg

Meqsel (Trametinib) is indicated for the treatment of patients with a type of skin cancer. It works by slowing the growth of cancer cells.

Meqsel in combination with dabrafenib is indicated for the treatment of patients with:

unresectable or metastatic melanoma with a BRAF V600 mutation. As a monotherapy, it is indicated for the treatment of patients with unresectable or metastatic melanoma
advanced non-small cell lung cancer (NSCLC)
thyroid cancer

Additional information

Trade Name	Meqsel
Generic Name	Trametinib -Dimethylsulfoxide
Manufacturer	Novartis India Ltd
Drug Type	Oncology
Indication	Lung Cancer
Doasage Form	Tablet
Packaging	30 tablets